Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pseudomonas Infections | 23 | 2024 | 613 | 4.900 |
Why?
|
Pseudomonas Vaccines | 9 | 2022 | 23 | 3.460 |
Why?
|
Pseudomonas aeruginosa | 26 | 2024 | 1219 | 2.850 |
Why?
|
Pneumonia, Bacterial | 11 | 2018 | 316 | 1.900 |
Why?
|
Burkholderia Infections | 6 | 2021 | 44 | 1.530 |
Why?
|
Burkholderia cepacia complex | 3 | 2021 | 25 | 1.200 |
Why?
|
Burkholderia | 5 | 2021 | 38 | 1.200 |
Why?
|
Cystic Fibrosis | 11 | 2024 | 1177 | 1.180 |
Why?
|
Pneumonia, Ventilator-Associated | 5 | 2022 | 274 | 1.160 |
Why?
|
Pneumonia | 7 | 2024 | 2133 | 0.950 |
Why?
|
Antibodies, Bacterial | 12 | 2022 | 1470 | 0.950 |
Why?
|
Th17 Cells | 4 | 2022 | 766 | 0.920 |
Why?
|
Bacterial Proteins | 9 | 2022 | 3848 | 0.850 |
Why?
|
Catheter-Related Infections | 3 | 2022 | 252 | 0.740 |
Why?
|
Antigens, Bacterial | 2 | 2018 | 1171 | 0.710 |
Why?
|
Bacteremia | 6 | 2020 | 962 | 0.680 |
Why?
|
Cross Infection | 6 | 2022 | 1416 | 0.670 |
Why?
|
Respiration, Artificial | 6 | 2023 | 2569 | 0.660 |
Why?
|
Lactobacillus | 1 | 2019 | 189 | 0.650 |
Why?
|
Interleukin-17 | 4 | 2018 | 899 | 0.610 |
Why?
|
Hemeproteins | 1 | 2017 | 62 | 0.580 |
Why?
|
Drug Resistance, Bacterial | 3 | 2022 | 1035 | 0.550 |
Why?
|
Probiotics | 1 | 2019 | 351 | 0.540 |
Why?
|
Point Mutation | 1 | 2021 | 1623 | 0.540 |
Why?
|
Colony Count, Microbial | 1 | 2015 | 331 | 0.490 |
Why?
|
Respiratory Tract Infections | 1 | 2022 | 961 | 0.490 |
Why?
|
Evolution, Molecular | 2 | 2021 | 1940 | 0.480 |
Why?
|
Mandatory Reporting | 1 | 2015 | 121 | 0.480 |
Why?
|
Drug Carriers | 1 | 2018 | 693 | 0.470 |
Why?
|
Flagellin | 3 | 2021 | 125 | 0.460 |
Why?
|
Bacterial Infections | 1 | 2022 | 1401 | 0.450 |
Why?
|
Vaccines, Attenuated | 7 | 2012 | 342 | 0.450 |
Why?
|
Biofilms | 2 | 2018 | 617 | 0.450 |
Why?
|
2-Propanol | 1 | 2013 | 28 | 0.440 |
Why?
|
Flagella | 3 | 2018 | 103 | 0.440 |
Why?
|
Bacterial Vaccines | 3 | 2006 | 403 | 0.420 |
Why?
|
Disinfectants | 1 | 2013 | 116 | 0.400 |
Why?
|
Equipment Contamination | 1 | 2013 | 185 | 0.400 |
Why?
|
Chlorhexidine | 1 | 2013 | 162 | 0.400 |
Why?
|
Ventilators, Mechanical | 4 | 2023 | 292 | 0.380 |
Why?
|
Corneal Ulcer | 1 | 2012 | 169 | 0.380 |
Why?
|
Disinfection | 1 | 2013 | 191 | 0.380 |
Why?
|
Peptic Ulcer | 2 | 2024 | 223 | 0.380 |
Why?
|
Anti-Bacterial Agents | 11 | 2023 | 7181 | 0.370 |
Why?
|
Anesthetics, Inhalation | 3 | 2021 | 570 | 0.370 |
Why?
|
Catheters, Indwelling | 1 | 2013 | 426 | 0.370 |
Why?
|
Neutropenia | 3 | 2012 | 895 | 0.360 |
Why?
|
Macrophage Activation Syndrome | 2 | 2022 | 111 | 0.350 |
Why?
|
Lipopolysaccharides | 5 | 2018 | 2216 | 0.340 |
Why?
|
Polysaccharides, Bacterial | 1 | 2012 | 578 | 0.340 |
Why?
|
Sepsis | 4 | 2023 | 2593 | 0.310 |
Why?
|
O Antigens | 4 | 2010 | 193 | 0.310 |
Why?
|
Lung | 12 | 2021 | 9856 | 0.310 |
Why?
|
Stenotrophomonas maltophilia | 2 | 2017 | 16 | 0.300 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2022 | 260 | 0.290 |
Why?
|
Disease Models, Animal | 15 | 2018 | 18029 | 0.280 |
Why?
|
Shock, Septic | 2 | 2023 | 775 | 0.270 |
Why?
|
Drug Discovery | 1 | 2014 | 1058 | 0.270 |
Why?
|
Administration, Intranasal | 4 | 2018 | 446 | 0.270 |
Why?
|
Mice | 29 | 2024 | 81183 | 0.260 |
Why?
|
Virulence | 6 | 2021 | 1333 | 0.260 |
Why?
|
UTP-Glucose-1-Phosphate Uridylyltransferase | 1 | 2004 | 6 | 0.250 |
Why?
|
Immunocompromised Host | 2 | 2012 | 847 | 0.250 |
Why?
|
Eye Infections, Bacterial | 3 | 2006 | 235 | 0.250 |
Why?
|
Mice, Inbred C3H | 6 | 2012 | 964 | 0.240 |
Why?
|
Animals | 33 | 2024 | 168757 | 0.230 |
Why?
|
Intensive Care Units | 5 | 2023 | 3679 | 0.230 |
Why?
|
Immune Sera | 2 | 2022 | 641 | 0.220 |
Why?
|
Alkyl and Aryl Transferases | 2 | 2005 | 89 | 0.220 |
Why?
|
Antibodies, Neutralizing | 1 | 2012 | 1978 | 0.210 |
Why?
|
Mice, Inbred C57BL | 11 | 2021 | 21827 | 0.210 |
Why?
|
Staphylococcus aureus | 3 | 2015 | 1451 | 0.200 |
Why?
|
Surgical Wound Infection | 2 | 2021 | 1540 | 0.200 |
Why?
|
Toll-Like Receptor 5 | 1 | 2021 | 39 | 0.200 |
Why?
|
High-Frequency Ventilation | 1 | 2001 | 87 | 0.200 |
Why?
|
Bacterial Load | 2 | 2018 | 153 | 0.190 |
Why?
|
Work Capacity Evaluation | 1 | 2020 | 46 | 0.180 |
Why?
|
Vaccines, Synthetic | 2 | 2018 | 634 | 0.180 |
Why?
|
Anti-Ulcer Agents | 1 | 2020 | 119 | 0.170 |
Why?
|
Cornea | 3 | 2016 | 1524 | 0.170 |
Why?
|
Histamine H2 Antagonists | 1 | 2020 | 165 | 0.170 |
Why?
|
Keratitis | 2 | 2016 | 268 | 0.170 |
Why?
|
Phagocytosis | 5 | 2018 | 1539 | 0.170 |
Why?
|
General Practitioners | 1 | 2020 | 103 | 0.170 |
Why?
|
Drug Resistance, Microbial | 1 | 2022 | 862 | 0.170 |
Why?
|
Vaccines, Subunit | 1 | 2018 | 168 | 0.160 |
Why?
|
Isoflurane | 2 | 2021 | 380 | 0.160 |
Why?
|
Antibody Formation | 1 | 2022 | 1402 | 0.150 |
Why?
|
Child | 19 | 2023 | 77709 | 0.150 |
Why?
|
Peritoneal Cavity | 1 | 2017 | 148 | 0.150 |
Why?
|
Anaerobiosis | 1 | 2017 | 140 | 0.150 |
Why?
|
Bacterial Outer Membrane Proteins | 2 | 2018 | 404 | 0.150 |
Why?
|
Lac Operon | 1 | 2017 | 238 | 0.140 |
Why?
|
Swimming | 1 | 2018 | 206 | 0.140 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2024 | 1130 | 0.140 |
Why?
|
Total Quality Management | 1 | 1998 | 274 | 0.140 |
Why?
|
Cephalosporins | 1 | 2017 | 204 | 0.140 |
Why?
|
Genome, Bacterial | 2 | 2019 | 760 | 0.140 |
Why?
|
Phylogeny | 3 | 2019 | 2803 | 0.140 |
Why?
|
Selection, Genetic | 3 | 2017 | 914 | 0.140 |
Why?
|
Urinary Tract Infections | 1 | 2022 | 788 | 0.140 |
Why?
|
Antacids | 1 | 2016 | 99 | 0.140 |
Why?
|
Macrophage-1 Antigen | 1 | 2017 | 290 | 0.140 |
Why?
|
Cytokines | 4 | 2019 | 7322 | 0.130 |
Why?
|
Vaccination | 2 | 2012 | 3278 | 0.130 |
Why?
|
Intestinal Diseases | 1 | 2020 | 530 | 0.130 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 2017 | 378 | 0.130 |
Why?
|
Eye Infections, Fungal | 1 | 2016 | 110 | 0.130 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2017 | 232 | 0.130 |
Why?
|
Catheterization, Central Venous | 1 | 2020 | 514 | 0.130 |
Why?
|
Heart Defects, Congenital | 2 | 2024 | 4584 | 0.130 |
Why?
|
Humans | 46 | 2024 | 744343 | 0.130 |
Why?
|
Digestive System Surgical Procedures | 1 | 2020 | 576 | 0.130 |
Why?
|
Pneumonia, Staphylococcal | 1 | 2015 | 43 | 0.130 |
Why?
|
Acetylglucosamine | 1 | 2016 | 191 | 0.130 |
Why?
|
Antilymphocyte Serum | 1 | 2016 | 492 | 0.130 |
Why?
|
Infant | 11 | 2024 | 35136 | 0.120 |
Why?
|
Hydrocephalus | 1 | 2021 | 748 | 0.120 |
Why?
|
Neutrophils | 5 | 2021 | 3719 | 0.120 |
Why?
|
Spleen | 2 | 2012 | 2362 | 0.120 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 3870 | 0.120 |
Why?
|
Eye Infections | 1 | 2014 | 64 | 0.120 |
Why?
|
Quality Improvement | 3 | 2023 | 3749 | 0.110 |
Why?
|
Infant, Newborn | 10 | 2023 | 25625 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1375 | 0.110 |
Why?
|
Blood-Air Barrier | 1 | 2012 | 25 | 0.110 |
Why?
|
Macrophages | 2 | 2021 | 5655 | 0.110 |
Why?
|
Trehalose | 1 | 2013 | 88 | 0.110 |
Why?
|
8,11,14-Eicosatrienoic Acid | 1 | 2012 | 62 | 0.110 |
Why?
|
Immunoglobulin G | 2 | 2022 | 4560 | 0.110 |
Why?
|
Blood | 1 | 2015 | 598 | 0.110 |
Why?
|
Diarrhea | 1 | 2019 | 1348 | 0.110 |
Why?
|
Genes, Bacterial | 2 | 2018 | 1079 | 0.110 |
Why?
|
Mutation | 7 | 2022 | 29786 | 0.110 |
Why?
|
Receptors, Interleukin-17 | 1 | 2012 | 69 | 0.110 |
Why?
|
Female | 28 | 2021 | 380194 | 0.110 |
Why?
|
Arachidonate 12-Lipoxygenase | 1 | 2012 | 80 | 0.100 |
Why?
|
Blood Bactericidal Activity | 1 | 2012 | 126 | 0.100 |
Why?
|
Plant Diseases | 1 | 2013 | 150 | 0.100 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2014 | 1155 | 0.100 |
Why?
|
Transendothelial and Transepithelial Migration | 1 | 2012 | 102 | 0.100 |
Why?
|
Mice, Knockout | 6 | 2017 | 14557 | 0.100 |
Why?
|
Genetic Variation | 2 | 2019 | 6544 | 0.100 |
Why?
|
Survival Analysis | 4 | 2018 | 10252 | 0.100 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 687 | 0.100 |
Why?
|
Enteral Nutrition | 1 | 2016 | 763 | 0.090 |
Why?
|
Epithelial Cells | 2 | 2021 | 3690 | 0.090 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2017 | 1122 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2017 | 3701 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1607 | 0.090 |
Why?
|
Retrospective Studies | 12 | 2023 | 77449 | 0.090 |
Why?
|
Critical Illness | 4 | 2024 | 2670 | 0.090 |
Why?
|
Eye | 1 | 2014 | 729 | 0.090 |
Why?
|
Flow Cytometry | 2 | 2018 | 5974 | 0.090 |
Why?
|
Arabidopsis | 1 | 2013 | 459 | 0.090 |
Why?
|
Biomedical Research | 1 | 2005 | 3309 | 0.090 |
Why?
|
Adaptive Immunity | 1 | 2014 | 713 | 0.080 |
Why?
|
Immunity, Innate | 3 | 2009 | 2958 | 0.080 |
Why?
|
Immunotherapy | 2 | 2016 | 4445 | 0.080 |
Why?
|
Immunization | 3 | 2018 | 1256 | 0.080 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2015 | 780 | 0.080 |
Why?
|
Cell Line | 3 | 2018 | 15997 | 0.080 |
Why?
|
Serotyping | 1 | 2008 | 338 | 0.080 |
Why?
|
Intensive Care Units, Pediatric | 3 | 2022 | 981 | 0.080 |
Why?
|
Rabbits | 3 | 2006 | 4894 | 0.080 |
Why?
|
Caveolin 1 | 1 | 2009 | 263 | 0.080 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 7913 | 0.080 |
Why?
|
Disease Outbreaks | 1 | 2017 | 1772 | 0.070 |
Why?
|
Child, Preschool | 8 | 2021 | 41006 | 0.070 |
Why?
|
3-Phosphoshikimate 1-Carboxyvinyltransferase | 2 | 2005 | 6 | 0.070 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2007 | 179 | 0.070 |
Why?
|
Carrier State | 1 | 2010 | 518 | 0.070 |
Why?
|
Intestines | 1 | 2015 | 1924 | 0.070 |
Why?
|
Serpins | 1 | 2007 | 247 | 0.070 |
Why?
|
Phenotype | 2 | 2021 | 16365 | 0.070 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5867 | 0.060 |
Why?
|
Oxygen | 1 | 2017 | 4189 | 0.060 |
Why?
|
Staphylococcal Infections | 1 | 2014 | 1400 | 0.060 |
Why?
|
Hospital Mortality | 4 | 2023 | 5317 | 0.060 |
Why?
|
Hexuronic Acids | 1 | 2004 | 144 | 0.060 |
Why?
|
Glucuronic Acid | 1 | 2004 | 148 | 0.060 |
Why?
|
Clinical Competence | 1 | 2020 | 4687 | 0.060 |
Why?
|
Adolescent | 10 | 2021 | 85781 | 0.060 |
Why?
|
Infection Control | 2 | 2022 | 966 | 0.060 |
Why?
|
Genomics | 1 | 2019 | 5720 | 0.060 |
Why?
|
Lethal Dose 50 | 1 | 2003 | 77 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2014 | 4386 | 0.060 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2008 | 986 | 0.050 |
Why?
|
Pediatrics | 1 | 1998 | 3475 | 0.050 |
Why?
|
Ulcer | 1 | 2024 | 209 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2019 | 15519 | 0.050 |
Why?
|
Urinary Catheterization | 1 | 2022 | 202 | 0.050 |
Why?
|
Hospitals | 3 | 2022 | 3952 | 0.050 |
Why?
|
Inflammation | 1 | 2021 | 10638 | 0.050 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 437 | 0.050 |
Why?
|
Clindamycin | 1 | 2021 | 139 | 0.050 |
Why?
|
Klebsiella | 1 | 2000 | 48 | 0.050 |
Why?
|
Mice, Inbred Strains | 1 | 2003 | 1827 | 0.050 |
Why?
|
Interleukins | 2 | 2015 | 791 | 0.050 |
Why?
|
Pulmonary Gas Exchange | 1 | 2001 | 382 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2018 | 6171 | 0.040 |
Why?
|
Deoxyribonucleases | 1 | 2001 | 214 | 0.040 |
Why?
|
Cytotoxins | 1 | 2000 | 153 | 0.040 |
Why?
|
Sick Leave | 1 | 2020 | 110 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2020 | 10943 | 0.040 |
Why?
|
United States | 5 | 2022 | 69872 | 0.040 |
Why?
|
Klebsiella Infections | 1 | 2000 | 138 | 0.040 |
Why?
|
Pilot Projects | 2 | 2024 | 8324 | 0.040 |
Why?
|
Gastrointestinal Tract | 1 | 2005 | 814 | 0.040 |
Why?
|
Epidemics | 2 | 2017 | 523 | 0.040 |
Why?
|
Intestinal Mucosa | 1 | 2010 | 3036 | 0.040 |
Why?
|
Virulence Factors | 2 | 2013 | 509 | 0.040 |
Why?
|
Absenteeism | 1 | 2020 | 250 | 0.040 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 2020 | 264 | 0.040 |
Why?
|
Interleukin-8 | 1 | 2021 | 690 | 0.040 |
Why?
|
Internship and Residency | 1 | 1998 | 5788 | 0.040 |
Why?
|
Ohio | 1 | 1998 | 337 | 0.040 |
Why?
|
Escherichia coli | 2 | 2018 | 4217 | 0.040 |
Why?
|
Bronchoalveolar Lavage | 1 | 2017 | 120 | 0.040 |
Why?
|
Male | 14 | 2021 | 350118 | 0.040 |
Why?
|
Half-Life | 1 | 2017 | 661 | 0.040 |
Why?
|
Abscess | 1 | 2000 | 607 | 0.040 |
Why?
|
Antibiotic Prophylaxis | 1 | 2021 | 639 | 0.030 |
Why?
|
Mice, Inbred BALB C | 2 | 2002 | 6386 | 0.030 |
Why?
|
Infant, Premature, Diseases | 1 | 2001 | 706 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2024 | 9734 | 0.030 |
Why?
|
Organ Transplantation | 1 | 2005 | 1139 | 0.030 |
Why?
|
Prospective Studies | 4 | 2022 | 53288 | 0.030 |
Why?
|
Hospitals, Pediatric | 1 | 2023 | 1775 | 0.030 |
Why?
|
Neutrophil Infiltration | 1 | 2017 | 390 | 0.030 |
Why?
|
Retinal Diseases | 1 | 2000 | 683 | 0.030 |
Why?
|
Gene Deletion | 1 | 2002 | 2751 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 12072 | 0.030 |
Why?
|
Host-Pathogen Interactions | 2 | 2013 | 1477 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2017 | 976 | 0.030 |
Why?
|
Xylans | 1 | 2013 | 9 | 0.030 |
Why?
|
alpha-Amylases | 1 | 2013 | 41 | 0.030 |
Why?
|
Equipment Design | 1 | 2001 | 3582 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2018 | 2839 | 0.030 |
Why?
|
Anesthesia, General | 1 | 2020 | 1171 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2022 | 19905 | 0.030 |
Why?
|
Length of Stay | 2 | 2016 | 6309 | 0.030 |
Why?
|
Plants, Genetically Modified | 1 | 2013 | 110 | 0.030 |
Why?
|
Glucans | 1 | 2013 | 72 | 0.030 |
Why?
|
Respiratory Insufficiency | 1 | 2001 | 1199 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 1998 | 1179 | 0.030 |
Why?
|
Glucosyltransferases | 1 | 2013 | 98 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 943 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2023 | 2266 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2008 | 19229 | 0.030 |
Why?
|
Plant Leaves | 1 | 2013 | 143 | 0.030 |
Why?
|
Forced Expiratory Volume | 1 | 2017 | 1743 | 0.030 |
Why?
|
NF-kappa B | 1 | 2021 | 2499 | 0.030 |
Why?
|
Infant, Premature | 1 | 2001 | 2044 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2021 | 1889 | 0.030 |
Why?
|
Logistic Models | 2 | 2017 | 13408 | 0.030 |
Why?
|
Risk Factors | 4 | 2021 | 72290 | 0.030 |
Why?
|
Microbial Sensitivity Tests | 1 | 2017 | 1877 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2017 | 956 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 2682 | 0.020 |
Why?
|
Adaptation, Biological | 1 | 2011 | 153 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3778 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2203 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2021 | 2002 | 0.020 |
Why?
|
Cell Wall | 1 | 2013 | 422 | 0.020 |
Why?
|
Ciprofloxacin | 1 | 2011 | 315 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 2959 | 0.020 |
Why?
|
Lung Diseases | 2 | 2011 | 1886 | 0.020 |
Why?
|
Respiratory Mucosa | 1 | 2012 | 427 | 0.020 |
Why?
|
Gene Expression | 2 | 2018 | 7799 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2011 | 1005 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2004 | 9274 | 0.020 |
Why?
|
Immunity, Mucosal | 1 | 2010 | 490 | 0.020 |
Why?
|
Macrophages, Alveolar | 1 | 2009 | 407 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2013 | 1312 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3610 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12026 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 40561 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2018 | 13815 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 1998 | 2291 | 0.020 |
Why?
|
Bacterial Translocation | 1 | 2005 | 73 | 0.020 |
Why?
|
Boston | 1 | 1998 | 9313 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9849 | 0.020 |
Why?
|
Adult | 5 | 2022 | 214055 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16689 | 0.020 |
Why?
|
Cecum | 1 | 2005 | 237 | 0.020 |
Why?
|
Binding Sites, Antibody | 1 | 2004 | 349 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2024 | 63114 | 0.020 |
Why?
|
Peroxidase | 1 | 2007 | 611 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2006 | 1095 | 0.010 |
Why?
|
Hybridomas | 1 | 2004 | 452 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12959 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 9959 | 0.010 |
Why?
|
Immunoglobulin Variable Region | 1 | 2004 | 421 | 0.010 |
Why?
|
Immunization, Passive | 1 | 2006 | 623 | 0.010 |
Why?
|
Alginates | 1 | 2004 | 252 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2009 | 1782 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 20947 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12354 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2005 | 13695 | 0.010 |
Why?
|
Immunoblotting | 1 | 2005 | 1682 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7279 | 0.010 |
Why?
|
Cefotaxime | 1 | 2001 | 35 | 0.010 |
Why?
|
Lymphocytes | 1 | 2009 | 2617 | 0.010 |
Why?
|
Transformation, Genetic | 1 | 2000 | 192 | 0.010 |
Why?
|
Species Specificity | 1 | 2004 | 2478 | 0.010 |
Why?
|
Liver Abscess | 1 | 2000 | 82 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2017 | 21746 | 0.010 |
Why?
|
Prevalence | 1 | 2016 | 15226 | 0.010 |
Why?
|
Young Adult | 2 | 2017 | 56430 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 23338 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2005 | 2242 | 0.010 |
Why?
|
HIV Infections | 1 | 2005 | 16718 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13881 | 0.010 |
Why?
|
Models, Animal | 1 | 2005 | 2171 | 0.010 |
Why?
|
Laser Coagulation | 1 | 2000 | 326 | 0.010 |
Why?
|
Hospitalization | 1 | 2017 | 10262 | 0.010 |
Why?
|
Endophthalmitis | 1 | 2000 | 262 | 0.010 |
Why?
|
Vitrectomy | 1 | 2000 | 365 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 2001 | 1465 | 0.010 |
Why?
|
Fluorescein Angiography | 1 | 2000 | 940 | 0.010 |
Why?
|
DNA Primers | 1 | 2000 | 2892 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 15165 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 40075 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2004 | 6622 | 0.010 |
Why?
|
Animals, Newborn | 1 | 2000 | 2726 | 0.010 |
Why?
|
Acute Disease | 1 | 2004 | 7149 | 0.010 |
Why?
|
Visual Acuity | 1 | 2000 | 2530 | 0.010 |
Why?
|
Models, Biological | 1 | 2007 | 9583 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2000 | 6489 | 0.010 |
Why?
|
Base Sequence | 1 | 2000 | 12797 | 0.010 |
Why?
|
Middle Aged | 1 | 2017 | 213383 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2000 | 20129 | 0.000 |
Why?
|